On the mechanism for PPAR agonists to enhance ABCA1 gene expression

Atherosclerosis

Volumn 205, Issue 2, 2009, Pages 413-419

  Ogata, Masaki ^a   Tsujita, Maki ^a   Hossain, Mohammad Anwar ^a   Akita, Nobukatsu ^a   Gonzalez, Frank J ^b   Staels, Bart ^c,d,e   Suzuki, Shogo ^a   Fukutomi, Tatsuya ^a   Kimura, Genjiro ^a   Yokoyama, Shinji ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b NATIONAL CANCER INSTITUTE   (United States)

^c INSTITUT PASTEUR DE LILLE   (France)

^d INSERM   (France)

^e UNIV LILLE   (France)

Author keywords

ABCA1; Cholesterol; HDL; LXR; PPAR

Indexed keywords

2 [4 [3 [4,5 DIHYDRO 1 (4 METHYLBENZYL) 5 OXO 1H 1,2,4 TRIAZOL 3 YL]PROPYL]PHENOXY] 2 METHYLPROPIONIC ACID; ABC TRANSPORTER A1; APOLIPOPROTEIN A1; BEZAFIBRATE; FENOFIBRATE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; LIPID; LIVER X RECEPTOR ALPHA; LUCIFERASE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; SMALL INTERFERING RNA; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID;

ANIMAL CELL; ARTICLE; BIOGENESIS; CONTROLLED STUDY; ENZYME ACTIVITY; FETUS; FIBROBLAST; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LIPID TRANSPORT; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BEZAFIBRATE; CELL LINE, TUMOR; FENOFIBRATE; FIBROBLASTS; GEMFIBROZIL; GENE EXPRESSION REGULATION; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PPAR DELTA; PPAR GAMMA; PROPIONATES; THIAZOLES; THIAZOLIDINEDIONES; TRIAZOLES;

EID: 67651098675     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.01.008     Document Type: Article

References (31)

1. Yokoyama S. Assembly of high-density lipoprotein. Arterioscler Thromb Vasc Biol 26 (2006) 20-27
2. Singaraja R.R., Brunham L.R., Visscher H., Kastelein J.J., and Hayden M.R. Efflux and atherosclerosis: the clinical and biochemical impact of variations in the ABCA1 gene. Arterioscler Thromb Vasc Biol 23 (2003) 1322-1332
3. Staels B., Dallongeville J., Auwerx J., Schoonjans K., Leitersdorf E., and Fruchart J.C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98 (1998) 2088-2093
4. Chinetti G., Lestavel S., Bocher V., et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 7 (2001) 53-58
5. Arakawa R., Tamehiro N., Nishimaki-Mogami T., Ueda K., and Yokoyama S. Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent manner. Arterioscler Thromb Vasc Biol 25 (2005) 1193-1197
6. Cabrero A., Cubero M., Llaverias G., et al. Differential effects of peroxisome proliferator-activated receptor activators on the mRNA levels of genes involved in lipid metabolism in primary human monocyte-derived macrophages. Metabolism 52 (2003) 652-657
7. Peters J.M., Aoyama T., Burns A.M., and Gonzalez F.J. Bezafibrate is a dual ligand for PPARalpha and PPARbeta: studies using null mice. Biochim Biophys Acta 1632 (2003) 80-89
8. Hossain M.A., Tsujita M., Gonzalez F.J., and Yokoyama S. Effects of fibrate drugs on expression of ABCA1 and HDL biogenesis in hepatocytes. J Cardiovasc Pharmacol 51 (2008) 258-266
9. Sprecher D.L., Massien C., Pearce G., et al. Triglyceride: high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist. Arterioscler Thromb Vasc Biol 27 (2007) 359-365
10. Tall A.R. Cholesterol efflux pathways and other potential mechanism involved in the athero-protective effect of high density lipoproteins. J Intern Med 263 (2008) 256-273
11. Barter P., and Rye K.A. Is there a role of fibrate in the management of dyslipidemia in the metabolic syndrome?. Arterioscler Thromb Vasc Biol 28 (2008) 39-46
12. Rubins H.B., Robins S.J., Collins D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341 (1999) 410-418
13. Hirakata M., Tozawa R., Imura Y., and Sugiyama Y. Comparison of the effects of pioglitazone and rosiglitazone on macrophage foam cell formation. Biochem Biophys Res Commun 323 (2004) 782-788
14. Marx N., Duez H., Fruchart J.C., and Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 94 (2004) 1168-1178
15. Tontonoz P., Hu E., and Spiegelman B.M. Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma. Curr Opin Genet Dev 5 (1995) 571-576
16. Picard F., and Auwerx J. PPAR(gamma) and glucose homeostasis. Annu Rev Nutr 22 (2002) 167-197
17. Li A.C., Binder C.J., Gutierrez A., et al. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARα, β/δ, and γ. J Clin Invest 114 (2004) 1564-1576
18. Staels B., Maes M., and Zambon A. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease. Nat Clin Pract Cardiovasc Med 5 (2008) 542-553
19. Li A.C., and Glass C.K. PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis. J Lipid Res 45 (2004) 2161-2173
20. Oliver Jr. W.R., Shenk J.L., Snaith M.R., et al. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 98 (2001) 5306-5311
21. Lee C.H., Chawla A., Urbiztondo N., et al. Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science 302 (2003) 453-457
22. Vosper H., Patel L., Graham T.L., et al. The peroxisome proliferator-activated receptor delta promotes lipid accumulation in human macrophages. J Biol Chem 276 (2001) 44258-44265
23. Lee S.S., Pineau T., Drago J., et al. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol 15 (1995) 3012-3022
24. Xu Y., Mayhugh D., Saeed A., et al. Design and synthesis of a potent and selective triazolone-based peroxisome proliferator-activated receptor alpha agonist. J Med Chem 46 (2003) 5121-5124
25. Pineda Torra I., Jamshidi Y., Flavell D.M., Fruchart J.C., and Staels B. Characterization of the human PPARalpha promoter: identification of a functional nuclear receptor response element. Mol Endocrinol 16 (2002) 1013-1028
26. Suzuki S., Nishimaki-Mogami T., Tamehiro N., et al. Verapamil increases the apolipoprotein-mediated release of cellular cholesterol by induction of ABCA1 expression via Liver X receptor-independent mechanism. Arterioscler Thromb Vasc Biol 24 (2004) 519-525
27. Chawla A., Boisvert W.A., Lee C.H., et al. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 7 (2001) 161-171
28. Inoue J., Satoh S., Kita M., et al. PPARalpha gene expression is up-regulated by LXR and PXR activators in the small intestine. Biochem Biophys Res Commun 371 (2008) 675-678
29. Yoshikawa T., Ide T., Shimano H., et al. Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. I. PPARs suppress sterol regulatory element binding protein-1c promoter through inhibition of LXR signalling. Mol Endocrinol 17 (2003) 1240-1254
30. Ide T., Shimano H., Yoshikawa T., et al. Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. II. LXRs suppress lipid degradation gene promoters through inhibition of PPAR signalling. Mol Endocrinol 17 (2003) 1255-1267
31. Lu R., Arakawa R., Ito-Osumi C., Iwamoto N., and Yokoyama S. ApoA-I facilitates ABCA1 recycle/accumulation to cell surface by inhibiting its intracellular degradation and increases HDL generation. Arterioscler Thromb Vasc Biol 28 (2008) 2282-2287